Orexo (STO:ORX) said today that the European Medicines Agency granted marketing authorization for its Zubsolv rapidly-disintegrating treatment for opioid dependence.
The buprenorphine and naloxone sublingual tablet is the first to be approved in Europe with six different strengths, according to the Sweden-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Orexo nabs regulatory win for fast-dissolving opioid dependence therapy appeared first on MassDevice.
from MassDevice http://ift.tt/2hOQvH1
Cap comentari:
Publica un comentari a l'entrada